Colorectal Cancer

Colorectal cancer (CRC) presents formidable challenges in therapeutic development, driven by significant tumor heterogeneity, complex resistance mechanisms, and an alarming rise in early-onset disease. 

Finding the right laboratory partner becomes essential for navigating this challenging landscape, where comprehensive molecular profiling, advanced resistance monitoring, and adaptive testing strategies are crucial for developing therapies that can overcome the inherent complexity and therapeutic resistance characteristic of this prevalent disease. 

Here’s an overview of the unique solid tumour offerings at HBRI:

Intra-tumoral heterogeneity poses a major challenge for CRC treatment, as different cell subpopulations may respond variably or even resist therapy and promote recurrence. 

With essential biomarkers including KRAS, NRAS, BRAF, HER2, NTRK, RET, and critical markers like microsatellite instability (MSI), mismatch repair (MMR) status, and tumor mutational burden (TMB), the molecular complexity demands sophisticated testing approaches that can adapt to evolving resistance patterns. 

Understanding which biomarkers to test and when becomes crucial for treatment success, requiring laboratory partners with comprehensive expertise across multiple testing platforms.

Here’s how our testing capabilities support your lung cancer trials:

1.NCCN guidelines 2024; 2.Bebb et al. Curr Oncol 2021; *HBRI Data In-house mostly available through the ACTOnco®/Cerba France/Cerba US NGS panels or CR Montpellier (IHC) or Cerba France (FISH); IHC=immunohistochemistry; NGS=next-generation sequencing; FISH=fluorescence in situ hybridization; CEA=carcinoembryonic antigen determination; TMB=tumor mutation burden; MSI=microsatellite instability; dMMR= mismatch repair deficient

This comprehensive biomarker landscape requires seamless integration of NGS, IHC, and FISH methodologies to provide the complete molecular picture needed for precision treatment decisions in colorectal cancer.